|
FORM 8-K SECURITIES AND EXCHANGE COMMISSION
WASHINGTON
DC 20549 CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 MEDISCIENCE TECHNOLOGY CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED ON CHARTER) NEW JERSEY 0-7405 22-1937826 ____________________________________________________________________________________________________________ (State
of Incorporation) (Commission
File No.)
(IRS Employer Identification No.) 1235 Folkestone Way, P.O. Box 598, Cherry Hill, New Jersey 08003 ____________________________________________________________________________________________________________ Registrant�s telephone number. Including area code (856) 428 7952 ____________________________________________________________________________________________________________ _______________________________________________________________
(Former Address, if changed,
since last report) Item 5. Other Materially Important Events This disclosure is intended to satisfy: SEC Section 6, Regulation FD,
Section 6.01 Regulation FD Disclosure and Section 7 and 7.0 Other events. On
March 13,2003, On unanimous Board of Directors approval Registrant appointed Michael W. Engelhart to the
Mediscience Board of Directors effective immediately. �Exhibit A� Mr. Engelhart is President/CEO of
THMGROUP LLC, Ramsey NJ as exclusive advisor to explore options for the
registrant to commercialize its technology. Registrants 8-K dated January 22, 2003 is incorporated
herein by reference
Press Release Exhibit �A�
SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized MEDISCIENCE TECHNOLOGY CORPORATION
ss/Peter Katevatis
Peter
Katevatis, Chairman/CEO Dated March 14, 2003 |